• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

Introduction to 4,6-Difluoronicotinaldehyde (CAS No. 1806358-06-4)

4,6-Difluoronicotinaldehyde, identified by the Chemical Abstracts Service Number (CAS No.) 1806358-06-4, is a fluorinated derivative of nicotinaldehyde, a compound of significant interest in the field of organic synthesis and pharmaceutical chemistry. This compound has garnered attention due to its unique structural features and potential applications in the development of novel bioactive molecules. The presence of fluorine atoms at the 4 and 6 positions of the pyridine ring introduces specific electronic and steric properties, making it a valuable intermediate in synthetic chemistry and drug discovery.

The synthesis of 4,6-Difluoronicotinaldehyde involves strategic functionalization of the nicotinaldehyde backbone. The introduction of fluorine atoms can be achieved through various methods, including halogenation reactions and cross-coupling processes. These synthetic approaches are carefully designed to ensure high yield and purity, which are critical for subsequent applications in medicinal chemistry. The compound's reactivity makes it a versatile building block for constructing more complex molecules, particularly in the design of small-molecule inhibitors targeting biological pathways relevant to human health.

In recent years, there has been growing interest in fluorinated heterocycles due to their enhanced metabolic stability, improved binding affinity, and altered pharmacokinetic profiles compared to their non-fluorinated counterparts. 4,6-Difluoronicotinaldehyde exemplifies this trend, as its structure suggests potential applications in the development of kinase inhibitors, antiviral agents, and other therapeutic compounds. The fluorine atoms can modulate the electronic properties of the molecule, influencing its interactions with biological targets such as enzymes and receptors.

One of the most compelling aspects of 4,6-Difluoronicotinaldehyde is its role as a precursor in the synthesis of more complex pharmacophores. Researchers have leveraged this compound to develop novel scaffolds with improved pharmacological properties. For instance, derivatives of 4,6-Difluoronicotinaldehyde have been explored as potential inhibitors of protein-protein interactions involved in cancer progression. The ability to fine-tune the structure through fluorination allows for the optimization of key pharmacokinetic parameters, such as bioavailability and half-life.

The chemical properties of 4,6-Difluoronicotinaldehyde also make it a valuable tool in mechanistic studies. Its reactivity with various nucleophiles and electrophiles has been investigated to understand how fluorine substitution affects molecular interactions. These studies not only contribute to fundamental chemical knowledge but also provide insights into how fluorinated compounds can be engineered for better therapeutic efficacy. The compound's stability under different reaction conditions further enhances its utility as a synthetic intermediate.

Advances in computational chemistry have also played a significant role in understanding the behavior of 4,6-Difluoronicotinaldehyde. Molecular modeling studies have revealed how fluorine atoms influence the conformational flexibility and electronic distribution within the molecule. These insights are crucial for designing molecules with specific biological activities. Additionally, computational methods have been used to predict potential side effects and metabolic pathways associated with derivatives of this compound.

The pharmaceutical industry has shown particular interest in fluorinated compounds due to their favorable pharmacological profiles. 4,6-Difluoronicotinaldehyde is no exception, as it serves as a key intermediate in several drug discovery programs targeting neurological disorders, infectious diseases, and cancer. Its structural features allow for precise modifications that can enhance target specificity while minimizing off-target effects. This makes it an attractive candidate for further development into clinical candidates.

In conclusion,4,6-Difluoronicotinaldehyde (CAS No. 1806358-06-4) represents a significant advancement in synthetic organic chemistry and medicinal chemistry. Its unique structural features and reactivity make it a valuable tool for developing novel bioactive molecules with potential therapeutic applications. As research continues to uncover new synthetic strategies and pharmacological insights,4,6-Difluoronicotinaldehyde is likely to remain at the forefront of drug discovery efforts aimed at addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)